Do you want to skip to content? Skip to content
Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Convatec Group Plc [CTEC:LON] is pleased to announce that it has invested $30 million in BlueWind Medical, Ltd., (“BlueWind Medical”) as part of BlueWind Medical’s $64 million Series B funding round. This round of financing was led by Convatec. BlueWind Medical is the developer of RENOVA iStimTM, an implantable tibial neuromodulation device, currently in development, for the treatment of urge incontinence alone or in combination with urinary urgency and/or urinary frequency.

For Convatec this represents an investment into an innovative technology in the large and growing over-active bladder (OAB) market. This chronic condition affects over 34 million people in the U.S. alone, with 19 million actively seeking care. The RENOVA iStim device utilizes neuromodulation to target the nerves that control the bladder. RENOVA iStim is implanted near the ankle in a single short outpatient procedure of approximately 30 minutes utilising local anaesthesia.  In November the company completed patient enrollment of the OASIS pivotal clinical study at 23 centres in the US, UK, The Netherlands, and Belgium and interim safety data was recently announced showing no device or procedure related serious adverse events.  BlueWind Medical will submit an application for U.S. Food & Drug Administration (FDA) marketing clearance in the United States later in 2022 based on the OASIS pivotal study.

The investment supports Convatec’s FISBE strategy (Focus-Innovate-Simplify-Build-Execute) by securing a relationship with a company developing an innovative solution related to the US Continence space.  

 

Seth Segel, President & COO, Global Continence Care & Home Services Group at Convatec said: “This is an exciting opportunity to gain exposure to a new and innovative technology in the broader Continence Care space. We look forward to working closely with BlueWind Medical to improve the lives of people suffering from OAB.”

Dan Lemaitre, Chairman & CEO of BlueWind Medical, said: “We are pleased to welcome Convatec as an investor in BlueWind Medical. Their impressive footprint in the continence market and functional capability will provide highly valuable support as we strive to improve the lives of patients who deal with overactive bladder.”

 

About Convatec Group Plc

Convatec is a FTSE 250 global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. We have around 10,000 colleagues and sell our products and services in over 100 countries. Our vision is  Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Group revenues in 2021 were over $2 billion. To learn more about Convatec, please visit  https://www.convatecgroup.com

About BlueWind Medical Ltd.

BlueWind Medical was founded in Israel in 2010 and has an extensive patent portfolio including 15 patent families, 35 filings and 24 issued patents. BlueWind Medical obtained CE Mark for RENOVA iStim in the treatment of overactive bladder in 2016. The OASIS study is being conducted under an Investigational Device Exemption (IDE) from the FDA. RENOVA iStim is not approved for use in the U.S.

For additional information please visit  BlueWindMedical.com

Press Release

5/12/2022

5/12/2022

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

2/28/2022

2/28/2022

Non-Executive Directors - Appointment and Resignation

Non-Executive Directors - Appointment and Resignation

3/8/2022

3/8/2022

Annual Results for the twelve months ended 31 December 2021

Annual Results for the twelve months ended 31 December 2021

3/14/2022

3/14/2022

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment

5/13/2022

5/13/2022

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

5/12/2022

5/12/2022

AGM trading update for the four months ended 30 April 2022

AGM trading update for the four months ended 30 April 2022

1/27/2022

1/27/2022

Board committee changes

Board committee changes

5/18/2022

5/18/2022

Convatec makes 'forever caring' promise to patients and healthcare providers

Convatec makes 'forever caring' promise to patients and healthcare providers